Seoul Medical Group — $62.85M MA Risk-Adjustment Settlement

What happened

Seoul Medical Group Inc. (SMG), a Koreatown-based primary care provider, its subsidiary Advanced Medical Management Inc., its former president Dr. Min Young Cha, and a co-conspirator radiology group Renaissance Imaging Medical Associates Inc. agreed to pay a combined $62.85 million to resolve allegations under the False Claims Act.

The allegations cover conduct from 2015 through 2021. The government alleged that SMG submitted false diagnosis codes for two specific spinal conditions — spinal enthesopathy and sacroiliitis — that are expensive to treat and carry high risk scores under Medicare Advantage. The inflated diagnoses generated higher per-enrollee payments from the Medicare Advantage program for SMG's patient population.

What makes this case structurally distinct from earlier MA risk-adjustment settlements:

• Fabricated diagnoses, not just process asymmetry. The conduct in Kaiser and Independent Health centered on adding diagnoses through chart-review and addenda processes that were not symmetric. The SMG allegations went further: the diagnoses themselves were alleged to be unsupported by any clinical reality, and a radiology group was allegedly engaged to create fake reports to give the diagnoses a veneer of legitimacy.
• Internal correction was refused. Per the complaint, Advanced Medical Management (AMM, SMG's audit subsidiary) detected the unsupported diagnoses in 2017 and recommended that SMG correct and delete them. SMG declined. SMG then acquired AMM in 2018 and terminated AMM personnel — including the future relator — in what the government characterized as an effort to "prevent any correction."
• Payor questioning was deflected. When one of SMG's MA payor partners questioned SMG's "dramatically increasing risk scores" in 2017, SMG allegedly claimed the diagnostic pattern was unique to the Korean patients SMG served — then engaged Renaissance to generate radiology reports supporting the diagnoses.

The settlement breakdown:

• SMG + Advanced Medical Management: $58.74 million
• Dr. Min Young Cha (personally): $1.76 million
• Renaissance Imaging Medical Associates: $2.35 million

The case originated as a qui tam action filed in 2020 by Paul Pew, the former Vice President and Chief Financial Officer of Advanced Medical Management — the same AMM whose 2017 correction recommendations SMG had declined. DOJ partially intervened in March 2025 to effectuate the settlement. The relator's share has not yet been determined.

Why this matters — for compliance officers

Three things compliance officers at MA-affiliated provider organizations should hold onto from this case:

1. Internal correction recommendations create permanent risk records. When AMM recommended correction in 2017 and SMG declined, the recommendation itself became enforcement evidence. Every compliance officer's correction memo, every internal audit finding, every retained-counsel risk assessment is a document the government can subpoena. The operational lesson: don't generate correction recommendations you aren't prepared to act on. If you do generate them, act on them. Inaction is the worst possible response to internal discovery.

2. The acquire-and-terminate pattern is its own enforcement signal. SMG's acquisition of AMM and termination of AMM personnel was a primary fact in the government's complaint — not because acquisitions are unusual but because the timing relative to the unfavorable correction recommendation was. M&A activity that occurs shortly after internal compliance concerns arise should be papered carefully, with the governance trail explaining the business rationale independent of compliance history.

3. Co-conspirator liability extends to support services. Renaissance Imaging was a radiology group that produced reports to support SMG's diagnosis submissions. Renaissance settled for $2.35 million. The lesson for compliance officers in radiology, pathology, laboratory, and other diagnostic-support relationships: producing reports that downstream practices use to support MA risk-adjustment submissions can carry independent FCA exposure. Ordering practices and the practices they contract with for diagnostic support both own the resulting risk surface.

What ArrowISE learns from this case

Defensibility Index dimensions implicated. The Seoul Medical Group case, like Kaiser and Independent Health, primarily implicates Medicare Advantage coding-process integrity rather than the Stark Law / AKS arrangement compliance that is ArrowISE's core domain.

However, one element of the SMG case translates with unusual clarity to arrangement compliance: the radiology-group co-conspirator structure. The financial relationship between SMG and Renaissance Imaging — where one entity paid another to produce documentation supporting government submissions — is structurally identical to the kinds of third-party valuation and consulting relationships that underpin physician arrangements. When an FMV opinion is produced by a valuation firm that has a financial relationship with the hospital seeking the opinion, the same enforcement risk surface appears: was the documentation produced to support a substantive judgment, or to support a predetermined submission? ArrowISE's Defensibility Index captures FMV opinion issuer information explicitly, making vendor-attribution visible alongside the contract record.

Schena-Shield™ pattern rules informed by this case:

Across Kaiser, Independent Health, and Seoul Medical Group, the three Medicare Advantage cases now in the ArrowISE enforcement library establish a consistent structural lesson: asymmetric documentation processes are the enforcement signal, regardless of whether the asymmetry is in chart review, addenda submission, vendor relationships, or diagnostic-support arrangements. ArrowISE addresses this pattern in its core Stark/AKS arrangement-compliance domain through the FMV Sentinel's symmetric monitoring of opinion expiration regardless of direction.

The numbers